https://eureka.patsnap.com/resources/blog/rd-blog/imaging-based-in-situ-profiling-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Spatial Omics
Imaging-Based In Situ Profiling Patents: Filing Trends and Who Holds the Claim Space
  • Concentrated but not locked up. the top 5 assignees hold 23.4% of all 8,836 records in scope, and the top 10 hold 34.6% — leaving most of the field to a long tail of single- and few-filing entrants.
  • Filing has cooled from its 2022 peak. annual filings hit 404 in 2022, and complete-year data shows a -36% drop from 2021 (349) to 2024 (223) — though 2025-2026 figures are still filling in due to publication lag.
  • Momentum has stalled at the very top. several of the highest-cited assignees show zero filings in the latest tracked year, with the two most active leaders both posting steep year-on-year declines.
Get a prior-art report on your approach
8,836
Published Records
23%
Top-5 Share of All Records
-36%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (349 records) with 2024 (223) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,836 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··8 min readSourced from Patsnap Eureka
Overview

What this landscape covers

Imaging-based in situ profiling sits at the intersection of molecular detection and microscopy: methods for reading nucleic acid or protein signals directly inside intact tissue or cells, rather than after extraction. This landscape tracks patent filings that combine core techniques — in situ hybridization, in situ sequencing and multiplexed imaging — with the practical constraints that determine whether a method actually works at scale: optical crowding, decoding error rate, probe design, autofluorescence background, imaging cycle time and panel size limit.

The dataset spans 8,836 published records from January 2015 through July 2026, drawing on assignees ranging from diagnostics companies to academic medical centres. The claims here span everything from foundational probe chemistry to downstream bioinformatics pipelines, which is why the IPC composition below shows heavy overlap between molecular biology and analytical measurement classes.

Filing volume and technology composition, 2015-2026
  1. 1GENOMIC HEALTH INC668
  2. 2ATYR PHARM INC410
  3. 3PANGU BIOPHARMA LTD396
  4. 410X GENOMICS INC365
  5. 5KURA ONCOLOGY INC229
  6. 6PIONEER HI BREED INTERNATIONAL INC219
  7. 7CARIS MPI INC217
  8. 8NSABP FOUNDATION INC191
  9. 9SOMALOGIC OPERATING CO INC187
  10. 10RGT UNIV OF CALIFORNIA178
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers

Filing trend and technology composition

Two views of the same 8,836 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.

Filing activity peaked in 2022 and has since declined

Annual filings rose from 322 in 2017 to a peak of 404 in 2022. Using only complete years, filings fell -36% from 349 in 2021 to 223 in 2024. Data for 2025 and 2026 is still incomplete because publication typically lags filing by roughly 18 months, so the apparent drop in the most recent one or two years should not be read as the field slowing further.

Filing activity peaked in 2022 and has since declined0125250375500322201720182019202020214042022202320242025182026Most recent year is partial — publication lag means later filings are not yet visible.

Claims cluster around enzymatic and analytical measurement classes

C12Q (measuring and testing involving enzymes or DNA) appears in 67.9% of the 8,836 records, far ahead of G01N (material analysis and testing) at 29.0% and C12N (microorganisms and genetic engineering) at 27.4%. Because a single record can carry multiple IPC classes, these shares add up to well over 100% — they show where claim density sits, not a partition of the field.

Claims cluster around enzymatic and analytical measurement classesC12Q · Measuring & testing involving …6,00367.9%G01N · Material analysis & testing2,56529.0%C12N · Microorganisms & genetic engin…2,42427.4%A61K · Medicinal preparations1,62918.4%C07K · Peptides & proteins1,30414.8%G16B · Bioinformatics8509.6%C07H · Sugars & nucleic acids8369.5%A61P · Therapeutic activity of compou…8279.4%Other3,78942.9%

Shares are the percentage of the 8,836 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Imaging Based In Situ Profiling with Eureka

This page is one run against one query. Ask Eureka your own question about imaging based in situ profiling and every answer comes back with the patent numbers behind it.

Try Eureka
Foundational Filings

Key patents shaping the field

Representative Filing
WO1998006875A11998-02-19

Caged fluorochrome-labeled probes and subtraction of autofluorescence background (WO1998006875A1)

UNIVERSITY OF MASSACHUSETTS

Filed by the University of Massachusetts, this 1998 filing discloses a method for removing autofluorescence background from microscopic or flow cytometry images by comparing fluorescence readings before and after "uncaging" a caged fluorochrome label on a probe. The approach applies to fluorescent in situ hybridization images and to tracking a target molecule inside a living cell, and it also discloses a fluorochrome-uncaging flow cytometer.One of the earliest filings in this dataset to directly address autofluorescence background as a named technical constraint, rather than treating it as incidental imaging noise.

WO1998006875A1 — patent drawing 1WO1998006875A1 — patent drawing 2
View full filing
Most-cited records in this landscape
#Publication no.Patent titleCitations
1US5925517ADetectably labeled dual conformation oligonucleotide probes, assays and kits2,942
2WO1997031256A2Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays870
3US6103476ADetectably labeled, dual conformation oligonucleotide probes, assays and kits673
4US6852487B1Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays667
5WO2006084132A2Reagents, methods, and libraries for bead-based squencing585
6WO2008021290A2Organ-specific proteins and methods of their use521
7US7709198B2Multiplex detection of nucleic acids510
8US20130116130A1Digital Counting of Individual Molecules by Stochastic Attachment of Diverse Label-Tags451
9US8951726B2Multiplex detection of nucleic acids432
10US8604182B2Multiplex detection of nucleic acids432

Ranked by citation count within the searched corpus. Older filings accumulate more citations simply by being available longer, so treat this as a measure of influence on subsequent filers, not of current commercial relevance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the data means for filing strategy

Three patterns stand out once volume, composition and citation data are read together.

Concentration
23.4% / 34.6%
top 5 / top 10 share of all records

The top of the field is crowded, the rest is open

The top 5 assignees combined account for 23.4% of the 8,836 records in scope, and the top 10 for 34.6%. That leaves roughly two-thirds of the field distributed across a long tail of the ranked leaders and unranked filers, which is unusual concentration for a field this size but still far from a lockout.

Ranking covers 100 assignees, counted in records.
Momentum
-36%
2021 → 2024 filing change

Growth has cooled from its 2022 high

Filings peaked at 404 in 2022 after climbing from 322 in 2017. Using only complete years, the drop from 349 filings in 2021 to 223 in 2024 works out to -36% over that span — a real cooling, not an artifact of publication lag, since 2024 is the last year with a complete count.

2025-2026 figures will rise as publication catches up.
Class overlap
67.9%
of records touch C12Q

Molecular biology and imaging claims are deeply intertwined

C12Q leads at 67.9% of records, but G01N (29.0%), C12N (27.4%) and A61K (18.4%) all appear at meaningful share, and G16B bioinformatics classes still reach 9.6%. Most filings in this space combine a molecular or chemistry claim with an analytical or software claim rather than sitting in one class alone.

Shares sum above 100% because records carry multiple IPC classes.
Citation base
2,942 citations
on the single most-cited record

A handful of 1990s probe patents still anchor the field

The most-cited record in this corpus, US5925517A on dual-conformation oligonucleotide probes, carries 2,942 citations, well ahead of the next-ranked filings. That concentration of citations on older foundational probe chemistry is typical of a searched corpus and signals influence on later filers rather than continued commercial relevance.

Citation counts favour earlier-filed records by construction.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to imaging based in situ profiling, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing

Leading assignees and where they are active

The ranked leaders span diagnostics firms, genomics platform companies and academic research institutions, with filing activity split between core probe chemistry and downstream analysis pipelines.

Leader
668 records
leading assignee's total

One assignee sits well ahead of the field

The top-ranked assignee holds 668 records, nearly three times the fifth-place total of 229. That gap suggests a sustained, multi-year filing programme rather than a single burst of activity.

Fifth place: 229 records. Tenth place: 178 records.
Recent activity
-94% YoY
leading genomics platform filer

Even active filers have pulled back sharply

One of the more prolific recent filers recorded only 3 filings in the latest tracked year, down 94% year-on-year, while several other ranked leaders show zero filings in that same window. This is consistent with the broader post-2022 cooling rather than an isolated event.

Momentum figures reflect the latest tracked year, which is still incomplete.
Collaboration
355 co-filings
strongest co-assignee pair

A small number of tight filing partnerships stand out

The strongest co-assignee pairing in this dataset accounts for 355 joint records, far ahead of the next pairing at 183. Only 10 co-assignee pairs are recorded overall, so most filers in this field are not filing jointly.

10 co-assignee pairs recorded across the dataset.
🔍
Under-claimed technical sub-areas
Branches where filing density is comparatively thin relative to the core probe and imaging claims
decoding error correction schemesimaging cycle time reductionpanel size scaling beyond current limitsautomated probe design softwareautofluorescence background subtraction methods
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
10x Genomics, Inc.3-94%
SomaLogic Operating Co., Inc.1-86%
Genomic Health, Inc.0—
aTyr Pharma, Inc.0—
Pangu Biopharma Limited0—
Kura Oncology, Inc.0—
Caris MPI, Inc.0-100%
Pioneer Hi-Bred International, Inc.0-100%
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The dataset points to a field with a crowded core and open edges. The next steps depend on whether the goal is freedom-to-operate, licensing, or identifying where to file next.

Map freedom-to-operate against the top filers

With 23.4% of records held by five assignees, a targeted clearance search against just the top-ranked holders will surface most of the blocking claims before a broader search is needed.

Run a freedom-to-operate check in Eureka

Probe the under-claimed branches

Panel size scaling, decoding error correction and imaging cycle time show thinner filing density than core probe chemistry, making them candidates for new claim territory.

Explore white space in Eureka

Track momentum shifts among leaders

Several top assignees show zero or sharply declining recent filings, which can signal a shift in strategy, licensing-out, or a move to trade secret protection worth monitoring.

Set up assignee monitoring in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Imaging Based In Situ Profiling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Imaging Based In Situ Profiling in depth with Eureka

Go past this page: query the whole imaging based in situ profiling corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.